 SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 PRNewswire -- IDEAYA Biosciences, Inc. Nasdaq:IDYA, an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In FPI in the Phase 1 combination study of IDE196... 